The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia

Metabolism: Clinical and Experimental

Volumn 68, Issue , 2017, Pages 31-42

  Li, Dong Jie ^a   Li, Yong Hua ^b   Yuan, Hong Bin ^b   Qu, Le Feng ^b   Wang, Pei ^c  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia; Irisin; Neuroinflammation; Neuroprotection; Physical exercise

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRISIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; PROTEIN KINASE B; SUPEROXIDE; TUMOR NECROSIS FACTOR; FIBRONECTIN; FNDC5 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; ONCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL INFILTRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXERCISE; INTRACELLULAR SIGNALING; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERAPY EFFECT; WEIGHT REDUCTION; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CEREBRAL ARTERY DISEASE; DRUG EFFECTS; HUMAN; METABOLISM; NERVE CELL; NEUROLOGIC DISEASE; PATHOLOGY; RAT; STROKE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN ISCHEMIA; FIBRONECTINS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NERVOUS SYSTEM DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; ONCOGENE PROTEIN V-AKT; PC12 CELLS; PHYSICAL CONDITIONING, ANIMAL; RATS; SIGNAL TRANSDUCTION; STROKE;

EID: 85006341192     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.12.003     Document Type: Article

References (60)

1. [1] Bostrom, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481 (2012), 463–468.
2. [2] Loffler, D., Muller, U., Scheuermann, K., Friebe, D., Gesing, J., Bielitz, J., et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab 100 (2015), 1289–1299.
3. [3] Samy, D.M., Ismail, C.A., Nassra, R.A., Circulating irisin concentrations in rat models of thyroid dysfunction – effect of exercise. Metabolism 64 (2015), 804–813.
4. [4] Tsuchiya, Y., Ando, D., Takamatsu, K., Goto, K., Resistance exercise induces a greater irisin response than endurance exercise. Metabolism 64 (2015), 1042–1050.
5. [5] Jedrychowski, M.P., Wrann, C.D., Paulo, J.A., Gerber, K.K., Szpyt, J., Robinson, M.M., et al. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab 22 (2015), 734–740.
6. [6] Lee, P., Linderman, J.D., Smith, S., Brychta, R.J., Wang, J., Idelson, C., et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab 19 (2014), 302–309.
7. [7] Marcher, A.B., Loft, A., Nielsen, R., Vihervaara, T., Madsen, J.G., Sysi-Aho, M., et al. RNA-Seq and mass-spectrometry-based Lipidomics reveal extensive changes of Glycerolipid pathways in Brown adipose tissue in response to cold. Cell Rep 13 (2015), 2000–2013.
8. [8] Tsuchiya, Y., Ijichi, T., Goto, K., Effect of sprint training on resting serum irisin concentration - Sprint training once daily vs. twice every other day. Metabolism 65 (2016), 492–495.
9. [9] Raschke, S., Elsen, M., Gassenhuber, H., Sommerfeld, M., Schwahn, U., Brockmann, B., et al. Evidence against a beneficial effect of irisin in humans. PLoS One, 8, 2013, e73680.
10. [10] Albrecht, E., Norheim, F., Thiede, B., Holen, T., Ohashi, T., Schering, L., et al. Irisin - a myth rather than an exercise-inducible myokine. Sci Rep, 5, 2015, 8889.
11. [11] Polyzos, S.A., Mantzoros, C.S., An update on the validity of irisin assays and the link between irisin and hepatic metabolism. Metabolism 64 (2015), 937–942.
12. [12] Bostrom, P.A., Fernandez-Real, J.M., Metabolism: irisin, the metabolic syndrome and follistatin in humans. Nat Rev Endocrinol 10 (2014), 11–12.
13. [13] Huh, J.Y., Mantzoros, C.S., Irisin physiology, oxidative stress, and thyroid dysfunction: what next?. Metabolism 64 (2015), 765–767.
14. [14] Qiu, S., Cai, X., Yin, H., Zugel, M., Sun, Z., Steinacker, J.M., et al. Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism 65 (2016), 825–834.
15. [15] Polyzos, S.A., Mathew, H., Mantzoros, C.S., Irisin: a true, circulating hormone. Metabolism 64 (2015), 1611–1618.
16. [16] Baka, S., Malamitsi-Puchner, A., Boutsikou, T., Boutsikou, M., Marmarinos, A., Hassiakos, D., et al. Cord blood irisin at the extremes of fetal growth. Metabolism 64 (2015), 1515–1520.
17. [17] Joung, K.E., Park, K.H., Filippaios, A., Dincer, F., Christou, H., Mantzoros, C.S., Cord blood irisin levels are positively correlated with birth weight in newborn infants. Metabolism 64 (2015), 1507–1514.
18. [18] Zhang, Y., Li, R., Meng, Y., Li, S., Donelan, W., Zhao, Y., et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63 (2014), 514–525.
19. [19] Liu, T.Y., Shi, C.X., Gao, R., Sun, H.J., Xiong, X.Q., Ding, L., et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clin Sci (Lond) 129 (2015), 839–850.
20. [20] Tang, H., Yu, R., Liu, S., Huwatibieke, B., Li, Z., Zhang, W., Irisin inhibits hepatic cholesterol synthesis via AMPK-SREBP2 signaling. EBioMedicine 6 (2016), 139–148.
21. [21] Roca-Rivada, A., Castelao, C., Senin, L.L., Landrove, M.O., Baltar, J., Belen Crujeiras, A., et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One, 8, 2013, e60563.
22. [22] Wang, S., Pan, J., Irisin ameliorates depressive-like behaviors in rats by regulating energy metabolism. Biochem Biophys Res Commun 474 (2016), 22–28.
23. [23] Yong Qiao, X., Nie, Y., Xian Ma, Y., Chen, Y., Cheng, R., Yao Yinrg, W., et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci Rep, 6, 2016, 18732.
24. [24] Colaianni, G., Cuscito, C., Mongelli, T., Pignataro, P., Buccoliero, C., Liu, P., et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci U S A 112 (2015), 12157–12162.
25. [25] Brondani, L.A., Boelter, G., Assmann, T.S., Leitao, C.B., Canani, L.H., Crispim, D., Irisin-encoding gene (FNDC5) variant is associated with changes in blood pressure and lipid profile in type 2 diabetic women but not in men. Metabolism 64 (2015), 952–957.
26. [26] Zhu, D., Wang, H., Zhang, J., Zhang, X., Xin, C., Zhang, F., et al. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol 87 (2015), 138–147.
27. [27] Han, F., Zhang, S., Hou, N., Wang, D., Sun, X., Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway. Am J Physiol Heart Circ Physiol 309 (2015), H1501–H1508.
28. [28] Lu, J., Xiang, G., Liu, M., Mei, W., Xiang, L., Dong, J., Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-null diabetic mice. Atherosclerosis 243 (2015), 438–448.
29. [29] Li, D.J., Huang, F., Lu, W.J., Jiang, G.J., Deng, Y.P., Shen, F.M., Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxford) 213 (2015), 711–721.
30. [30] Longa, E.Z., Weinstein, P.R., Carlson, S., Cummins, R., Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20 (1989), 84–91.
31. [31] Namura, S., Iihara, K., Takami, S., Nagata, I., Kikuchi, H., Matsushita, K., et al. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A 98 (2001), 11569–11574.
32. [32] Nishida, H., Sohara, E., Nomura, N., Chiga, M., Alessi, D.R., Rai, T., et al. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension 60 (2012), 981–990.
33. [33] Wang, P., Xu, T.Y., Guan, Y.F., Su, D.F., Fan, G.R., Miao, C.Y., Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81 (2009), 370–380.
34. [34] Li, D.J., Evans, R.G., Yang, Z.W., Song, S.W., Wang, P., Ma, X.J., et al. Dysfunction of the cholinergic anti-inflammatory pathway mediates organ damage in hypertension. Hypertension 57 (2011), 298–307.
35. [35] Li, D.J., Fu, H., Zhao, T., Ni, M., Shen, F.M., Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle. Metabolism 65 (2016), 747–756.
36. [36] Wang, P., Guan, Y.F., Du, H., Zhai, Q.W., Su, D.F., Miao, C.Y., Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy 8 (2012), 77–87.
37. [37] Wang, P., Xu, T.Y., Guan, Y.F., Tian, W.W., Viollet, B., Rui, Y.C., et al. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol 69 (2011), 360–374.
38. [38] Sasaki, M., Otani, T., Kawakami, M., Ishikawa, S.E., Elevation of plasma retinol-binding protein 4 and reduction of plasma adiponectin in subjects with cerebral infarction. Metabolism 59 (2010), 527–532.
39. [39] Lu, L.F., Yang, S.S., Wang, C.P., Hung, W.C., Yu, T.H., Chiu, C.A., et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 18 (2009), 354–359.
40. [40] Wang, P., Miao, C.Y., NAMPT as a therapeutic target against stroke. Trends Pharmacol Sci 36 (2015), 891–905.
41. [41] Du, X.L., Jiang, W.X., Lv, Z.T., Lower circulating irisin level in patients with diabetes mellitus: a systematic review and meta-analysis. Horm Metab Res, 2016.
42. [42] Kuloglu, T., Aydin, S., Eren, M.N., Yilmaz, M., Sahin, I., Kalayci, M., et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides 55 (2014), 85–91.
43. [43] Aydin, S., Aydin, S., Kobat, M.A., Kalayci, M., Eren, M.N., Yilmaz, M., et al. Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides 56 (2014), 141–145.
44. [44] Amantea, D., Tassorelli, C., Russo, R., Petrelli, F., Morrone, L.A., Bagetta, G., et al. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain. Cell Death Dis, 2, 2011, e238.
45. [45] Nishimura, M., Izumiya, Y., Higuchi, A., Shibata, R., Qiu, J., Kudo, C., et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117 (2008), 216–223.
46. [46] Basic Kes, V., Simundic, A.M., Nikolac, N., Topic, E., Demarin, V., Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 41 (2008), 1330–1334.
47. [47] Dun, S.L., Lyu, R.M., Chen, Y.H., Chang, J.K., Luo, J.J., Dun, N.J., Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience 240 (2013), 155–162.
48. [48] Piya, M.K., Harte, A.L., Sivakumar, K., Tripathi, G., Voyias, P.D., James, S., et al. The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab 306 (2014), E512–E518.
49. [49] Moon, H.S., Dincer, F., Mantzoros, C.S., Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism 62 (2013), 1131–1136.
50. [50] Song, H., Wu, F., Zhang, Y., Zhang, Y., Wang, F., Jiang, M., et al. Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS One, 9, 2014, e110273.
51. [51] Endres, M., Gertz, K., Lindauer, U., Katchanov, J., Schultze, J., Schrock, H., et al. Mechanisms of stroke protection by physical activity. Ann Neurol 54 (2003), 582–590.
52. [52] Powers, S.K., Quindry, J.C., Kavazis, A.N., Exercise-induced cardioprotection against myocardial ischemia–reperfusion injury. Free Radic Biol Med 44 (2008), 193–201.
53. [53] Mahady, S.E., George, J., Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1172–1182.
54. [54] Rosenbaum, S., Tiedemann, A., Berle, D., Ward, P.B., Zachary, S., Exercise as a novel treatment option to address cardiometabolic dysfunction associated with PTSD. Metabolism 64 (2015), e5–e6.
55. [55] Terada, T., Wilson, B.J., Myette-Comicronte, E., Kuzik, N., Bell, G.J., McCargar, L.J., et al. Targeting specific interstitial glycemic parameters with high-intensity interval exercise and fasted-state exercise in type 2 diabetes. Metabolism 65 (2016), 599–608.
56. [56] Karstoft, K., Wallis, G.A., Pedersen, B.K., Solomon, T.P., The effects of interval- vs. continuous exercise on excess post-exercise oxygen consumption and substrate oxidation rates in subjects with type 2 diabetes. Metabolism 65 (2016), 1316–1325.
57. [57] Liu, X., Niu, Y., Yuan, H., Huang, J., Fu, L., AMPK binds to Sestrins and mediates the effect of exercise to increase insulin-sensitivity through autophagy. Metabolism 64 (2015), 658–665.
58. [58] Ray Hamidie, R.D., Yamada, T., Ishizawa, R., Saito, Y., Masuda, K., Curcumin treatment enhances the effect of exercise on mitochondrial biogenesis in skeletal muscle by increasing cAMP levels. Metabolism 64 (2015), 1334–1347.
59. [59] Wrann, C.D., White, J.P., Salogiannnis, J., Laznik-Bogoslavski, D., Wu, J., Ma, D., et al. Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway. Cell Metab 18 (2013), 649–659.
60. [60] Jodeiri Farshbaf, M., Ghaedi, K., Megraw, T.L., Curtiss, J., Shirani Faradonbeh, M., Vaziri, P., et al. Does PGC1alpha/FNDC5/BDNF elicit the beneficial effects of exercise on neurodegenerative disorders?. Neuromol Med 18 (2016), 1–15.